See more : Quinsam Capital Corporation (QCAAF) Income Statement Analysis – Financial Results
Complete financial analysis of Enanta Pharmaceuticals, Inc. (ENTA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Enanta Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Aros Bostadsutveckling AB (publ) (AROS.ST) Income Statement Analysis – Financial Results
- HLB Life Science Co., Ltd. (067630.KQ) Income Statement Analysis – Financial Results
- Nomad Foods Limited (NOMD) Income Statement Analysis – Financial Results
- Enomoto Co.,Ltd. (6928.T) Income Statement Analysis – Financial Results
- Monadelphous Group Limited (MND.AX) Income Statement Analysis – Financial Results
Enanta Pharmaceuticals, Inc. (ENTA)
About Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 67.64M | 79.20M | 86.16M | 97.07M | 122.47M | 205.20M | 206.63M | 102.81M | 88.27M | 160.88M | 47.74M | 32.05M | 41.71M | 41.88M | 22.76M |
| Cost of Revenue | 0.00 | 0.00 | 2.97M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 67.64M | 79.20M | 83.19M | 97.07M | 122.47M | 205.20M | 206.63M | 102.81M | 88.27M | 160.88M | 47.74M | 32.05M | 41.71M | 41.88M | 22.76M |
| Gross Profit Ratio | 100.00% | 100.00% | 96.55% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 131.48M | 163.52M | 164.52M | 174.11M | 136.76M | 142.21M | 94.86M | 57.45M | 40.46M | 23.19M | 18.74M | 16.84M | 15.12M | 11.55M | 9.72M |
| General & Administrative | 57.85M | 52.89M | 45.48M | 32.54M | 27.36M | 26.25M | 23.44M | 20.75M | 16.97M | 13.54M | 10.02M | 6.18M | 5.30M | 0.00 | 6.11M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 57.85M | 52.89M | 45.48M | 32.54M | 27.36M | 26.25M | 23.44M | 20.75M | 16.97M | 13.54M | 10.02M | 6.18M | 5.30M | 5.04M | 6.11M |
| Other Expenses | 0.00 | 0.00 | 83.00K | 1.99M | 6.62M | 8.82M | 4.79M | 2.33M | 1.72M | 1.31M | 283.00K | 598.00K | 0.00 | 5.04M | 309.00K |
| Operating Expenses | 189.33M | 216.41M | 210.00M | 206.65M | 164.11M | 168.46M | 118.30M | 78.20M | 57.43M | 36.73M | 28.76M | 23.02M | 20.42M | 16.58M | 15.82M |
| Cost & Expenses | 189.33M | 216.41M | 210.00M | 206.65M | 164.11M | 168.46M | 118.30M | 78.20M | 57.43M | 36.73M | 28.76M | 23.02M | 20.42M | 16.58M | 15.82M |
| Interest Income | 14.77M | 11.36M | 1.57M | 2.02M | 6.47M | 8.82M | 0.00 | 2.53M | 1.74M | 968.00K | 467.00K | 248.00K | 118.00K | 83.00K | 14.00K |
| Interest Expense | 10.94M | 5.15M | 1.57M | 0.00 | 0.00 | 8.82M | 4.85M | 40.00K | 45.00K | 8.00K | 18.00K | 31.00K | 0.00 | 3.16M | 0.00 |
| Depreciation & Amortization | 2.34M | 2.37M | 2.97M | 3.33M | 3.64M | 3.26M | 2.52M | 2.14M | 1.66M | 639.00K | 352.00K | 221.00K | 172.00K | 499.00K | 553.00K |
| EBITDA | -104.51M | -123.48M | -119.22M | -104.25M | -38.00M | 40.00M | 90.85M | 26.75M | 32.50M | 124.79M | 19.34M | 9.25M | 21.57M | 26.97M | 8.30M |
| EBITDA Ratio | -154.52% | -155.90% | -140.38% | -112.88% | -34.00% | 17.90% | 42.75% | 23.94% | 34.94% | 77.17% | 39.77% | 28.17% | 51.74% | 61.80% | 34.35% |
| Operating Income | -121.69M | -137.21M | -123.84M | -109.57M | -41.64M | 36.74M | 88.33M | 24.61M | 30.84M | 124.15M | 18.99M | 9.03M | 21.29M | 25.30M | 6.94M |
| Operating Income Ratio | -179.92% | -173.23% | -143.74% | -112.88% | -34.00% | 17.90% | 42.75% | 23.94% | 34.94% | 77.17% | 39.77% | 28.17% | 51.05% | 60.41% | 30.50% |
| Total Other Income/Expenses | 3.90M | 6.21M | 1.66M | 1.99M | 6.62M | 8.82M | 4.79M | 2.33M | 1.72M | 1.31M | 283.00K | 598.00K | 110.00K | -1.99M | 805.00K |
| Income Before Tax | -117.79M | -131.00M | -122.19M | -107.58M | -35.02M | 45.56M | 93.12M | 26.95M | 32.56M | 125.46M | 19.27M | 9.63M | 21.40M | 23.31M | 7.75M |
| Income Before Tax Ratio | -174.15% | -165.39% | -141.82% | -110.82% | -28.59% | 22.20% | 45.07% | 26.21% | 36.89% | 77.98% | 40.36% | 30.03% | 51.31% | 55.66% | 34.03% |
| Income Tax Expense | -1.74M | 2.82M | -433.00K | -28.58M | 1.15M | -826.00K | 21.17M | 9.24M | 10.89M | 46.46M | -15.17M | -221.00K | 0.00 | 3.16M | -157.00K |
| Net Income | -116.05M | -133.82M | -121.76M | -79.00M | -36.17M | 46.38M | 71.96M | 17.71M | 21.67M | 78.99M | 34.44M | 9.63M | 21.40M | 23.31M | 7.90M |
| Net Income Ratio | -171.58% | -168.95% | -141.31% | -81.38% | -29.53% | 22.60% | 34.82% | 17.23% | 24.55% | 49.10% | 72.14% | 30.03% | 51.31% | 55.66% | 34.72% |
| EPS | -5.48 | -6.38 | -5.91 | -3.92 | -1.81 | 2.37 | 3.48 | 0.93 | 1.14 | 4.23 | 1.88 | -0.67 | 1.18 | 1.35 | 0.02 |
| EPS Diluted | -5.48 | -6.38 | -5.91 | -3.92 | -1.81 | 2.21 | 3.48 | 0.91 | 1.13 | 4.09 | 1.80 | -0.67 | 0.52 | 0.59 | 0.02 |
| Weighted Avg Shares Out | 21.16M | 20.97M | 20.60M | 20.17M | 19.94M | 19.58M | 20.65M | 19.07M | 18.93M | 18.67M | 18.36M | 9.79M | 1.16M | 1.16M | 12.75M |
| Weighted Avg Shares Out (Dil) | 21.16M | 20.97M | 20.60M | 20.17M | 19.94M | 20.97M | 20.65M | 19.41M | 19.22M | 19.30M | 19.19M | 9.79M | 2.64M | 2.64M | 14.13M |
Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Misses Revenue Estimates
Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.36 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $1.33 per share a year ago.
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2024
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today reported financial results for its fiscal fourth quarter and year-ended September 30, 2024. “Our fiscal fourth quarter was...
Enanta Pharmaceuticals (ENTA) Surges 5.6%: Is This an Indication of Further Gains?
Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV)
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With RSV.
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates
Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.07 per share versus the Zacks Consensus Estimate of a loss of $1.49. This compares to loss of $1.86 per share a year ago.
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter.
Enanta Pharmaceuticals (ENTA) Soars 6.7%: Is Further Upside Left in the Stock?
Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Enanta Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product...
Enanta Pharmaceuticals to Participate at the JMP Securities Life Sciences Conference
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product...
Enanta Pharmaceuticals, Inc. (ENTA) Q2 2024 Earnings Call Transcript
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA ) Q2 2024 Earnings Conference Call May 6, 2024 4:30 PM ET Company Participants Jennifer Viera - Investor Relations Jay Luly - President and Chief Executive Officer Paul Mellett - Chief Financial Officer Scott Rottinghaus -...
Source: https://incomestatements.info
Category: Stock Reports